Oral mucositis is a debilitating side effect of cancer treatment. There is no FDA-approved treatment for oral mucositis in patients undergoing treatment for solid tumors. While many treatment approaches have failed, dusquetide (an Innate Defense Regulator and the active ingredient in SGX942) is unique in its mechanism addressing the underlying innate immune dysfunction that contributes to the severity and duration of mucositis. Administered twice weekly by a brief 4-minute IV infusion during chemoradiation treatment while patients are otherwise present at their clinician’s office or hospital, SGX942 may be a clinically convenient and safe approach to mitigating oral mucositis. Our pivotal Phase 3 clinical study (“DOM-INNATE”) for oral mucositis in head and neck cancer patients has completed enrollment. Topline efficacy results are expected in 4Q 2020.
Mucositis is the damage done to the lining of the mouth and gut by cancer treatment regimens. Severe Oral Mucositis (SOM) occurs when the damage to the mouth is so severe a patient’s ability to eat and/or drink is compromised. For patients already undergoing cancer treatment, an added inability to eat and/or drink means they are more likely to be dehydrated and malnourished, and are more susceptible to life-threatening infections. On average, patients with mucositis have a reduced quality of life, take more pain medications such as opioids, and spend more time in hospital. For some patients, SOM causes them to stop their cancer treatment, potentially impacting long term survival.
Mucositis of either the mouth or gut occurs in most different cancer treatment regimens. In head and neck cancer, 95% of patients have some form of oral mucositis and over 70% have SOM.
Despite these procedures, SOM still occurs in large numbers of patients, impacting quality of life, increasing the likelihood of hospital admissions and an increasing likelihood of stopping all anti-cancer treatment, potentially impacting long term survival.
The DOM-INNATE study evaluating SGX942 treatment of oral mucositis in head and neck cancer has completed recruitment throughout the US and Europe. Topline efficacy results are expected in 4Q 2020.
SGX942 is a rapid 4-minute infusion administered twice per week during chemotherapy and/or radiation treatment and is under investigation to reduce the duration and severity of severe oral mucositis.
What is SGX942?
SGX942 is an intravenous formulation of the Innate Defense Regulator, dusquetide, for the treatment of SOM.
What are Innate Defense Regulators?
Innate Defense Regulators (IDRs) are a new class of compound that change the response of the innate immune system by decreasing inflammation and increasing anti-infective and tissue healing activities.
Oral mucositis is driven by dysfunction of the innate immune system, and IDRs reset the innate immune response – mitigating the damaging inflammatory response caused by the chemotherapy and radiation.
Dusquetide is the first IDR to be tested in the clinic.
What is dusquetide?
Dusquetide is a drug composed of 5 amino acids, naturally occurring molecules which make up the proteins in your body. Therefore, metabolism of dusquetide results in additional building blocks for your body and is not known to interfere with any other drugs you may be taking.
What is Innate Immunity?
The innate immune system is the pre-programmed response arm of the immune system. By two years of age, most people’s innate immune system is fully functional. In order to identify threats, the innate immune looks for common “response patterns” or signals in different types of tissue damage and infections.
The innate immune system is your body’s rapid response team to deal with immediate threats (infection, wounds, radiation damage, etc.).
How Innate Immunity Works
The innate immune system is characterized by many different “damage detectors” (receptors) that people are born with.
The damage detectors respond immediately (there is no need to wait for the immune system to ‘learn’ anything). This is the primary difference between innate immunity (immediate response) and adaptive immunity (learned response of T-cells and antibodies where the learning process can take days or weeks).
Triggering the damage detectors launches both inflammatory responses as well as tissue healing and anti-infective responses.
Regardless of the damage detectors activated, only a few proteins inside the cell are responsible for dictating the immediate response of the innate immune system.
Mechanism of Action
Unlike other attempts to modulate the innate immune response, IDRs, like dusquetide, are unique because they target the intracellular control pathways including the protein p62 of the innate immune system – changing the character of the innate immune response. They decrease or control the inflammatory component and increase the tissue healing or anti-infective component. The effect on the innate immune response is immediate (within 30 minutes) and long-lasting (up to 5 days).
Cellular Response to Dusquetide Treatment
Within the cells, dusquetide binds to the protein known as p62 or sequestosome-1. Binding to this protein changes the balance of activation between inflammatory and non-inflammatory pathways.
More details on the mechanism of action of SGX942/dusquetide can be found in our Reference Literature.
Clinical Studies & Commercialization
We are currently conducting clinical research with SGX942 in oral mucositis in head and neck cancer patients. The DOM-INNATE trial (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) is a pivotal Phase 3 trial enrolling in the United States and Europe. With a recently completed interim analysis suggesting positive outcomes and recommending enrollment of up to 260 evaluable subjects in the trial, we completed enrollment in 2Q 2020.
Further information on the SGX942 program can be found in this webcast discussing our Phase 2 results.
Interested in partnering with us for commercializing in specific geographical regions?